ClinicalTrials.gg
RecruitingNCT05775588Updated Oct 5, 2026

Long-term Effects of Endobronchial Valve Implantation on Cardiac Function and Skeletal Muscle Function

An interventional study of Lung volume reduction surgery with endobronchial valve implantation in Chronic Obstructive Pulmonary Disease, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.
Updated Oct 5, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital — 16 open to participants now, 17 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · China-Japan Friendship Hospital.

Planned enrollment
11th of 13
100 · median 360
Started
2023
with 7 others
No phase
13 of 24
9 open now
Primary completion
2028-12
later than 16 of 16 live
Registered
9th of 24
by date

Among the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 8 that started in 2023, is one of 13 with no phase, reaches primary completion later than 16 of the 16 other live ones, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

16 of the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, or all of them as a file.
02

Study summary

The goal of this type of study: clinical trial is to evaluate the effect of bronchial valve implantation on cardiac function and skeletal muscle function in Chronic Obstructive Pulmonary Disease. The main question it aims to answer are:evaluate the effect of bronchial valve implantation on cardiac function and skeletal muscle function.

Participants will undergo Lung volume reduction surgery with endobronchial valve implantation.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with
  • ≤ 45% pred and FEV1/FVC\<70%
  • TLC>100% pred and RV>175% pred
  • CAT score≥18
  • Emphysema damage>50%
  • Complete interlobar fissure >95% based on quantitative analysis of CT measurement
  • No smoking>6 months
  • Sign the form

Exclusion criteria

Exclusion Criteria:

  • PaCO2>8.0 kPa, or PaO2\<6.0 kPa
  • 6-minute walk test\<160m
  • Obvious chronic bronchitis, bronchiectasis or other infectious pulmonary diseases
  • More than 3 hospitalizations for pulmonary infection in the past 12 months before baseline assessment
  • Previous lobectomy, LVRS or lung transplantation
  • \<45% and or RVSP>50mmHg
  • Anticoagulant therapy that cannot be stopped before surgery
  • Patients with obvious immune deficiency
  • Participated in other lung drug studies within the first 30 days of this study
  • Pulmonary nodules requiring intervention
  • Any disease or condition that interferes with the completion of the initial or subsequent assessment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Lung volume reduction surgery group

    Procedure: Lung volume reduction surgery with endobronchial valve implantation

Interventions

  • ProcedureLung volume reduction surgery with endobronchial valve implantation

    the patient would undergo Lung volume reduction surgery with endobronchial valve implantation

06

What researchers measure

Primary outcomes

  1. Baseline ventricular volume

    cardiac magnetic resonance imaging

    Time frame: Baseline

  2. Ventricular volume (6 months after surgery)

    cardiac magnetic resonance imaging

    Time frame: 6 months after surgery

  3. Ventricular volume(12 months after surgery)

    cardiac magnetic resonance imaging

    Time frame: 12 months after surgery

  4. Baseline FEV1

    Pulmonary function tests

    Time frame: Baseline

  5. FEV1 (6 months after surgery)

    Pulmonary function tests

    Time frame: 6 months after surgery

  6. FEV1(12 months after surgery)

    Pulmonary function tests

    Time frame: 12 months after surgery

  7. Baseline left Ventricular Ejection Fractions

    Echocardiography

    Time frame: Baseline

  8. Left Ventricular Ejection Fractions (6 months after surgery)

    Echocardiography

    Time frame: 6 months after surgery

  9. Left Ventricular Ejection Fractions (12 months after surgery)

    Echocardiography

    Time frame: 12 months after surgery

  10. Baseline exercise tolerance

    6-minute walk test

    Time frame: Baseline

  11. Exercise tolerance (6 months after surgery)

    6-minute walk test

    Time frame: 6 months after surgery

  12. Exercise tolerance (12 months after surgery)

    6-minute walk test

    Time frame: 12 months after surgery

  13. Baseline health impairment and quality of life of patients Baseline health impairment and quality of life of patients

    St. George's Respiratory Questionnaire

    Time frame: Baseline

  14. Health impairment and quality of life of patients (6 months after surgery)

    St. George's Respiratory Questionnaire

    Time frame: 6 months after surgery

  15. Health impairment and quality of life of patients (12 months after surgery)

    St. George's Respiratory Questionnaire

    Time frame: 12 months after surgery

  16. Baseline cross sectional area of rectus femoris

    Rectus femoris ultrasound

    Time frame: Baseline

  17. Cross sectional area of rectus femoris (6 months after surgery)

    Rectus femoris ultrasound

    Time frame: 6 months after surgery

  18. Cross sectional area of rectus femoris (12 months after surgery)

    Rectus femoris ultrasound

    Time frame: 12 months after surgery

  19. Baseline mmuscle strength of lower limb

    Myometer

    Time frame: Baseline

  20. Mmuscle strength of lower limb (6 months after surgery)

    Myometer

    Time frame: 6 months after surgery

  21. Mmuscle strength of lower limb (12 months after surgery)

    Myometer

    Time frame: 12 months after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2028, 69 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 69 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2024 → Dec 2028 and completion Dec 2024 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 20, 2023
StartActual
Mar 27, 2023
Primary completionEst.
Dec 31, 2028was Dec 2024
CompletionEst.
Dec 31, 2029was Dec 2024
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Oct 5, 2026
Sites
China-Japan Friendship Hospital is now Recruiting
Oct 5, 2026
Primary completion
Dec 31, 2024→Dec 31, 2028
Oct 5, 2026
Study completion
Dec 31, 2024→Dec 31, 2029
Oct 5, 2026
Enrollment
22 (actual)→100 (estimated)
Oct 5, 2026
Contact
Study contact now listed: added i•••@163.com · •••6854; added z•••@163.com · •••6167. See the current contact
Oct 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • China-Japan Friendship Hospital · Beijing, ChinaContact added h•••@163.com · •••5481Contact added i•••@163.com · •••6854
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Completed→Recruiting
    China-Japan Friendship Hospital is now Recruiting
    Primary completion Dec 31, 2024→Dec 31, 2028
    Study completion Dec 31, 2024→Dec 31, 2029
    Enrollment 22 (actual)→100 (estimated)
    Contact Study contact now listed: added i•••@163.com · •••6854; added z•••@163.com · •••6167. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • China-Japan Friendship Hospital · Beijing, ChinaContact added h•••@163.com · •••5481Contact added i•••@163.com · •••6854
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05775588
Responsible party
Gang Hou (Principal Investigator, China-Japan Friendship Hospital) — Principal investigator
First posted
Mar 20, 2023
Start date
Mar 27, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Mingming Deng, MD
Contact
isdeng1017@163.com
86 18801336854
Qin Zhang, MD
Contact
zhangqincmu@163.com
86 18990236167

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion